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Sulfa drugs are potent and important anti-pneumocystis agents, 
but have a high incidence of adverse effects in AIDS patients. 
Although 15,000 sulfa drugs have been synthesized and dozens 
have been used in people, relatively few have been tested against P. 
carinii. In order to determine whether there are sulfa drugs which 
are better antipneumocystis agents than sulfamethoxazole and 
dapsone, we have been testing sulfa drugs in vitro, against 
recombinant P. carinii dihydropteroate synthetase, and in vivo. 
MATERIALS AND METHODS. Immunosuppression of latently 
infected rats, isolation of organisms, and enzyme and uptake 
assays were performed as previously described ( I ) .  Rats were 
administered drug continuously via their drinking water for the full 
6 weeks of immunosuppression. Exact doses were calculated by 
measuring daily water consumption. After 6 weeks, the rats were 
sacrificed, organisms were harvested, and the total number of cysts 
isolated from the lungs of each rat determined. Mice were treated 
either prophylactically or therapeutically as previously described 
(2). 
RESULTS AND DISCUSSION. Of the 44 sulfa drugs studied 
initially, 8 had ICSO's between 13 and 4 0  p M :  
sulfamethoxypyridazole, sulfathiazole, sulfachlorpyridazine, 
sulfamethoxypyridazine, sulfathiourea, sulfadimethoxine, 
sulfisoxazole, and sulfaquinoxaline. In general, we found that 
sulfonamides (Fig. 1) were more potent than sulfones. The 
compounds with greatest potency tended to have heterocyclic 
substituents on the N1 position (R1). Substituents on the p-amino 
group (R2) ablated activity (I). 
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Fig. 1. Sulfonamide structure 
In order for a sulfa drug to be effective, i t  must not only inhibit 
dihydropteroate synthetase but be taken up by intact organisms. 
To determine this, we measured the effects of selected sulfa drugs on 
folate metabolism in intact, isolated P. carinii over 2 hours. At 
50 nM, sulfamethoxazole inhibited folate biosynthesis in situ by 
approximately half. Sulfachlorpyridazine, sulfamethoxypyri- 
dazine, sulfisoxazole, and sulfathiazole all inhibited folate 
biosynthesis to a similar extent at this concentration, suggesting 
that they are all taken up equally well by intact organisms (1). 
Sulfamethoxypyridazine and sulfisoxazole were selected for 
testing in animals, since they have both been widely used in 
humans. Both drugs were tested in transtracheally-inoculated mice 
using both prophylactic and therapeutic regimens (Table 1). On 
the basis of both Ciemsa and Silver scores, sulfisoxazole had 
moderate activity prophylactically but no activity therapeutically. 
In contrast, sulfamethoxypyridazine was equivalent to 
sulfamethoxazole both prophylactically and therapeutically. 
Table 1. Effects of sulfa drugs on P. carinii infections in mice. 
Drug Dose Mean infection (SD) - 
me/kdd(No.) G iem s a S ilv e r 
Control 0 (20) 4.4 (0.2) 3.6 (0.1) 
Therapy 
Sulfisoxazole 1.0 (10) 4.5 (0.1) 3.3 (0.1) 
Sulfamethoxypyridazine 1.0 (10) 0.3 (0.1) 0.2 (0.1) 
Sulfamethoxazole 1.0 (10) 0.1 (0.0) 0.1 (0.0) 
Prophylaxis 
Sulfisoxazole 1.0 (10) 1.4 (0.3) 1.6 (0.2) 
Sulfamethoxypyridazine 1.0 (10) 0.1 (0.1) 0.1 (0.1) 
Sulfamethoxazole 1.0 (10) 0.1 (0.0) 0.0 (0.0) 
Both drugs were also tested as prophylactic agents in latently 
infected rats (Table 2). Sulfisoxazole had no significant activity 
(not shown), whereas sulfamethoxypyridazine caused a >99% 
reduction i n  cyst counts at all doses tested. 
Table 2. Effects of sulfamethoxypyridazine on P. carinii infections 
Dose No. Percent P 
W d d )  rats reduction value 
15.4 4 99.8 0.02 
0 . 4  5 99 .5  0.05 
0.13 4 9 9 . 3  0.03 
In summary, sulfamethoxypyridazine was effective both 
prophylactically and therapeutically in mice and at impressively 
low doses in rats. The lowest dose tested in rats was 1/40th the 
sulfa dose received by patients on Bactrim prophylaxis 
(approximately 6 mg/kg/d) and 1/20th the the minimum effective 
dose of sulfamethoxazole in rats (3). It is possible that lower doses 
of sulfamethoxypyridazine, which are now being tested, may also 
prove to be effective. Sulfamethoxypyridazine deserves further 
consideration as an antipneumocystis drug for other reasons as 
well. First, i t  may possibly be associated with fewer adverse 
effects than sulfamethoxazole (4). Second, it has a longer half-life 
than sulfamethoxazole ( 5 )  making it more appropriate for 
prophylaxis. [Supported by NIH grants ROI-A1 31775, UOI-AI- 
35203 and NOl-AI-35171.] 
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